Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives

Overview

Journal J Clin Med

Specialty General Medicine

Date 2025 Feb 13

PMID 39941558

Authors

Ewelina Mlynarska

Kinga Bojdo

Hanna Frankenstein

Natalia Kustosik

Weronika Mstowska

Aleksandra Przybylak

Jacek Rysz

Beata Franczyk

Affiliations

Soon will be listed here.

Abstract

This narrative review explores emerging technologies in dyslipidemia management, focusing on nanotechnology and artificial intelligence (AI). It examines the current treatment recommendations and contrasts them with the future prospects enabled by these innovations. Nanotechnology shows significant potential in enhancing drug delivery systems, enabling more targeted and efficient lipid-lowering therapies. In parallel, AI offers advancements in diagnostics, cardiovascular risk prediction, and personalized treatment strategies. AI-based decision support systems and machine learning algorithms are particularly promising for analyzing large datasets and delivering evidence-based recommendations. Together, these technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care. In addition, this review covers key topics such as cardiovascular disease biomarkers and risk factors, providing insights into the current methods for assessing cardiovascular risk. It also discusses the current understanding of dyslipidemia, including pathophysiology and clinical management. Together, these insights and technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care.

References

Kosoglou T, Statkevich P, Johnson-Levonas A, Paolini J, Bergman A, Alton K . Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005; 44(5):467-94. DOI: 10.2165/00003088-200544050-00002. View

Mannu G, Zaman M, Gupta A, Rehman H, Myint P . Evidence of lifestyle modification in the management of hypercholesterolemia. Curr Cardiol Rev. 2012; 9(1):2-14. PMC: 3584303. DOI: 10.2174/157340313805076313. View

Hamilton S, Kingston B . Applying artificial intelligence and computational modeling to nanomedicine. Curr Opin Biotechnol. 2023; 85:103043. DOI: 10.1016/j.copbio.2023.103043. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Cai T, Abel L, Langford O, Monaghan G, Aronson J, Stevens R . Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021; 374:n1537. PMC: 8279037. DOI: 10.1136/bmj.n1537. View

Kulhari H, Kulhari D, Prajapati S, Chauhan A . Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. Mol Pharm. 2013; 10(7):2528-33. DOI: 10.1021/mp300650y. View

Mohammadpour R, Dobrovolskaia M, Cheney D, Greish K, Ghandehari H . Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev. 2019; 144:112-132. PMC: 6745262. DOI: 10.1016/j.addr.2019.07.006. View

Netala V, Teertam S, Li H, Zhang Z . A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024; 13(17. PMC: 11394358. DOI: 10.3390/cells13171471. View

Castro-Barquero S, Ruiz-Leon A, Sierra-Perez M, Estruch R, Casas R . Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nutrients. 2020; 12(10). PMC: 7600579. DOI: 10.3390/nu12102983. View

10.

Medina-Leyte D, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L . Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021; 22(8). PMC: 8068178. DOI: 10.3390/ijms22083850. View

11.

Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M . Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022; 344:80-96. PMC: 8851889. DOI: 10.1016/j.jconrel.2022.02.017. View

12.

Rakshit M, Darwitan A, Muktabar A, Das P, Nguyen L, Cao Y . Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models. Nanomedicine. 2021; 37:102434. DOI: 10.1016/j.nano.2021.102434. View

13.

Katta N, Loethen T, Lavie C, Alpert M . Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging. Curr Probl Cardiol. 2020; 46(3):100655. DOI: 10.1016/j.cpcardiol.2020.100655. View

14.

Lyngbakken M, Myhre P, Rosjo H, Omland T . Novel biomarkers of cardiovascular disease: Applications in clinical practice. Crit Rev Clin Lab Sci. 2018; 56(1):33-60. DOI: 10.1080/10408363.2018.1525335. View

15.

Wu S, Kersten S, Qi L . Lipoprotein Lipase and Its Regulators: An Unfolding Story. Trends Endocrinol Metab. 2020; 32(1):48-61. PMC: 8627828. DOI: 10.1016/j.tem.2020.11.005. View

16.

Gupta V, Paul S, Dutta C . Geography, Ethnicity or Subsistence-Specific Variations in Human Microbiome Composition and Diversity. Front Microbiol. 2017; 8:1162. PMC: 5481955. DOI: 10.3389/fmicb.2017.01162. View

17.

Traber G, Yu A . RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther. 2022; 384(1):133-154. PMC: 9827509. DOI: 10.1124/jpet.122.001234. View

18.

Larson D, Harvey H, Rubin D, Irani N, Tse J, Langlotz C . Regulatory Frameworks for Development and Evaluation of Artificial Intelligence-Based Diagnostic Imaging Algorithms: Summary and Recommendations. J Am Coll Radiol. 2020; 18(3 Pt A):413-424. PMC: 7574690. DOI: 10.1016/j.jacr.2020.09.060. View

19.

Ratwani R, Sutton K, Galarraga J . Addressing AI Algorithmic Bias in Health Care. JAMA. 2024; 332(13):1051-1052. DOI: 10.1001/jama.2024.13486. View

20.

P P A, Kumari S, Rajasimman A, Nayak S, Priyadarsini P . Machine learning predictive models of LDL-C in the population of eastern India and its comparison with directly measured and calculated LDL-C. Ann Clin Biochem. 2021; 59(1):76-86. DOI: 10.1177/00045632211046805. View